IN2012DN02692A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02692A
IN2012DN02692A IN2692DEN2012A IN2012DN02692A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A IN 2692DEN2012 A IN2692DEN2012 A IN 2692DEN2012A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A
Authority
IN
India
Prior art keywords
subunit
immunity against
inducing immunity
antigenic peptides
antibody
Prior art date
Application number
Other languages
English (en)
Inventor
Alice P Taylor
Body Makabi-Panzu
David M Goldenberg
Original Assignee
Ct Molecular Med & Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed by Ct Molecular Med & Immunology filed Critical Ct Molecular Med & Immunology
Publication of IN2012DN02692A publication Critical patent/IN2012DN02692A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IN2692DEN2012 2009-11-05 2010-10-29 IN2012DN02692A (enExample)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25836909P 2009-11-05 2009-11-05
US25872909P 2009-11-06 2009-11-06
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US37805910P 2010-08-30 2010-08-30
PCT/US2010/054668 WO2011056721A2 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines

Publications (1)

Publication Number Publication Date
IN2012DN02692A true IN2012DN02692A (enExample) 2015-09-04

Family

ID=43970701

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2692DEN2012 IN2012DN02692A (enExample) 2009-11-05 2010-10-29

Country Status (6)

Country Link
EP (1) EP2496256A4 (enExample)
CN (1) CN102573902A (enExample)
AU (1) AU2010315432A1 (enExample)
CA (1) CA2776563A1 (enExample)
IN (1) IN2012DN02692A (enExample)
WO (1) WO2011056721A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014047124A1 (en) * 2012-09-18 2014-03-27 University Of Washington Through Its Center For Commercialization Compositions and methods for delivery of antigens to plasmacytoid dendritic cells
AU2016215604B2 (en) 2015-02-02 2020-08-13 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
CN109187982B (zh) * 2018-08-02 2021-06-04 浙江康佰裕生物科技有限公司 一种tlr类疫苗佐剂的筛选和鉴定方法
CN113347993A (zh) * 2018-10-22 2021-09-03 艾赛澳克莱克斯疗法有限责任公司 突变牛痘病毒及其用途
CN111474339A (zh) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 一种利用荧光标记痘病毒颗粒的方法及其应用
WO2021219619A1 (en) * 2020-04-27 2021-11-04 Genovie Ab Methods to generate vaccine compositions that prime human leukocyte antigen class i restricted cd8 t-cell responses against viral non-virion-integral derived epitopes

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (en) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Hiv fusion polypeptide
DE69637523D1 (de) * 1995-06-07 2008-06-26 Sanofi Pasteur Ltd Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
CA2223577A1 (en) * 1995-06-07 1996-12-19 Connaught Laboratories Limited Chimeric antibodies for delivery of antigens to selected cells of the immune system
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
KR101017732B1 (ko) * 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-ｃｄ74 항체 및 그 이용방법
CA2484676A1 (en) * 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
US20050003403A1 (en) * 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
CN101171034B (zh) * 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
CA2607056C (en) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
CN105709237A (zh) * 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
CN101506358B (zh) * 2006-05-15 2013-07-17 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
BRPI0911427A2 (pt) * 2008-04-10 2015-11-17 Ibc Pharmaceuticals complexo por dnl (dock and lock) de anticorpo-citocina, uso de uma composição farmaceutica.

Also Published As

Publication number Publication date
AU2010315432A1 (en) 2012-04-12
CN102573902A (zh) 2012-07-11
CA2776563A1 (en) 2011-05-12
WO2011056721A3 (en) 2011-10-13
EP2496256A2 (en) 2012-09-12
EP2496256A4 (en) 2013-07-17
WO2011056721A2 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
WO2011056721A3 (en) Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines
WO2020193688A3 (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
MX2025008006A (es) Vacunas novedosas del vph16, composiciones y metodos de uso de las mismas
EA201492110A1 (ru) Вакцины против впг-2
MX2024004293A (es) Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika.
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
WO2012034025A3 (en) Human cytomegalovirus vaccine
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
MD4624B1 (ro) Virusuri oncolitice de vaccin variolic şi terapii imunooncolitice
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
MX2014012234A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
EA201892735A1 (ru) Состав вакцины против hiv
MY170659A (en) Nucleic acid molecules encoding hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
MX389111B (es) Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso.
EA201071366A1 (ru) Комбинированная вакцина против кори и вируса папилломы человека
EA201390806A1 (ru) Конструкция пептидного каркаса
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
WO2007034489A3 (en) Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom